January 2026 Research Update

This month, the clearest message is that a painful bone lesion, especially in the collarbone area, does not automatically mean CRMO or CNO, even in children. Across these studies, imaging helped look for multifocal disease (more than one bone area), and biopsies were commonly used when doctors needed to rule out other serious causes. This adds a practical picture of why diagnosis can take time and why the workup may include several steps. [1]

In a group of children evaluated for non-traumatic clavicle (collarbone) involvement, CNO was the most common final diagnosis, but it was not the only one. Other diagnoses included Langerhans cell histiocytosis, reactive arthritis, and Tietze syndrome, showing why clinicians try to keep an open differential when a single bone area is affected. Whole-body MRI often found additional silent lesions in children who ultimately had CNO, which supported the diagnosis of a multifocal inflammatory bone condition rather than a single local problem. [1]

A separate report focused on Chinese pediatric CRMO adds context about how CRMO tends to show up and why it can be missed early. Bone pain was very common, fever occurred in many children, and the tibia and femur were frequently involved on MRI. The authors noted that diagnostic delay could be long in some cases, which fits with the idea that CRMO can resemble infection or other bone diseases before the overall pattern becomes clear. [2]

For patients and caregivers, these studies help explain why clinicians may order whole-body imaging or recommend a biopsy during the diagnostic process: the goal is to confirm an inflammatory bone condition like CNO or CRMO while ruling out other diagnoses that can look similar at the start. This does not introduce a new diagnostic test that is ready to replace current practice, but it clarifies why the path to a diagnosis can be step-by-step and sometimes slow. What remains uncertain is the best way to shorten diagnostic delays across different health systems and settings, because these reports describe real-world practice rather than testing a single standardized approach. [1]

The Chinese case series and literature review also suggests that many children improve with anti-inflammatory treatments, but it does not settle which treatment plan is best for any individual child. It mainly adds a broader description of symptoms (like fever alongside bone pain) and common bone locations, which can help families understand why CRMO is sometimes mistaken for infection or other conditions early on. Long-term outcomes and recurrence rates were not clearly pinned down across the reviewed reports, so families may still encounter uncertainty when asking what to expect over years. [2]

This month, biology-focused studies did not settle on a single simple explanation for bone damage in CNO or CRMO. One laboratory study using patient blood cells did not see a consistent increase in osteoclast formation (cells that break down bone) in CNO compared with controls [3] , while another report tied a rare gene change to stronger inflammatory signaling and more osteoclast activity in a mouse model [4] . Together, these studies support the idea that CNO or CRMO biology may differ across patients rather than following one uniform pathway.

In the blood-cell laboratory study, osteoclast formation in culture looked similar across children with active CNO, inactive CNO, inactive juvenile idiopathic arthritis, and healthy controls. When researchers exposed healthy donor cells to patient serum, higher serum concentration led to more osteoclast formation, suggesting that circulating factors in blood can influence bone-resorbing activity in this test system. The study also reported that abatacept increased osteoclast formation in these cultures, which is an unexpected direction that needs more work to understand in real patients. [3]

A separate case report with mechanistic experiments described a patient with CRMO carrying an OGFRL1 loss-of-function variant and found signs of heightened inflammatory signaling. In a mouse model, OGFRL1 deficiency was linked to more severe arthritis and more bone erosion, along with greater osteoclast differentiation. The patient improved clinically and on inflammation blood tests after TNF inhibitor therapy, but this is still evidence from a single person combined with animal work, not proof that this gene explains CRMO for most families. [4]

For families, these studies mainly add to research understanding rather than changing what is done in routine care right now. The lab work suggests that in CNO, bone-resorbing cells may not always be intrinsically overactive in a simple blood-cell test, and that factors in the blood may matter in some settings. The rare genetic report provides an example of how a specific gene change could amplify inflammation and bone damage in one person, which may matter more in the future if similar cases are found. [3]

What remains uncertain is how well these laboratory and animal findings predict day-to-day symptoms, imaging changes, or treatment responses for most children with CNO or CRMO. The studies point to the possibility of different biological drivers in different people, which could eventually help explain why some children need stronger medicines while others do well on simpler approaches. For now, these results are best understood as early signals that help researchers decide what to test next. [4]

This month, single-patient reports added practical reminders about how varied bone inflammation can be. One child with CRMO also had psoriasis and noticeable nail changes that improved with treatment, suggesting that skin and nail clues can travel with bone symptoms in some children. [5] A separate report showed that a bone lesion that looks like osteomyelitis can be caused by a fungal infection, reinforcing why ruling out infection matters when symptoms and imaging are not typical. [6]

In the pediatric CRMO case, the child had multifocal bone involvement confirmed by imaging and biopsy, along with psoriasis and nail dystrophy (including trachyonychia). The report described improvement and remission with naproxen and methotrexate, with nail changes resolving over time, and a later relapse that again responded to methotrexate. The key addition is the emphasis that nail findings may be a visible clue that CRMO is part of a psoriatic pattern in some children. [5]

In the adult case, osteomyelitis was caused by Histoplasma capsulatum, confirmed on tissue testing rather than presumed from imaging alone. The patient improved after surgery plus intravenous amphotericin B, with no recurrence reported at 1 year. While this is not a CRMO report, it illustrates a major look-alike: an infectious bone problem that requires a different approach than nonbacterial bone inflammation. [6]

For families living with CRMO, the psoriasis-and-nail case is a reminder that symptoms outside the bones can sometimes be part of the same overall condition, and that noticing skin or nail changes may help connect the dots during evaluation. Because this is one child, it cannot tell how common nail findings are in CRMO, but it gives a concrete example of what clinicians may look for. This may matter now mostly for understanding the range of presentations rather than changing any standard tests or treatments by itself. [5]

The fungal osteomyelitis report matters mainly as background reassurance about why doctors may take infection seriously during the workup for bone lesions. It shows that even in an immunocompetent adult, infection can be localized to bone and can mimic other causes of bone pain on imaging. The uncertainty is how often these infectious look-alikes occur in people being evaluated for suspected CRMO, because a single case cannot provide rates or risk factors. [6]